eXoZymes, Inc.
$10.66
▲
3.55%
2026-04-21 06:45:02
www.exozymes.com
NCM: EXOZ
Explore eXoZymes, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$89.88 M
Current Price
$10.66
52W High / Low
$18.4 / $7.08
Stock P/E
—
Book Value
$0.4
Dividend Yield
—
ROCE
-220.6%
ROE
-1.33%
Face Value
—
EPS
$-1.09
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
32
Beta
—
Debt / Equity
36.59
Current Ratio
2.51
Quick Ratio
2.51
Forward P/E
—
Price / Sales
—
Enterprise Value
$97.41 M
EV / EBITDA
-10.33
EV / Revenue
—
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Tenax Therapeutics, Inc. | $14.1 | — | $247.99 M | — | -58.09% | -55.64% | $18.38 / $4.63 | $2.29 |
| 2. | Kura Oncology, Inc. | $9.78 | — | $863.87 M | — | -48.86% | -94.82% | $12.49 / $5.45 | $1.98 |
| 3. | UroGen Pharma Ltd. | $24.92 | — | $1.21 B | — | -81.06% | 268.63% | $30 / $3.42 | $-2.18 |
| 4. | Artiva Biotherapeutics, Inc. | $13.39 | — | $310.19 M | — | -76.21% | -56.55% | $13.2 / $1.47 | $4.53 |
| 5. | INmune Bio Inc. | $1.49 | — | $39.61 M | — | -128.97% | -1.65% | $11.64 / $1.09 | $0.89 |
| 6. | Ardelyx, Inc. | $6.3 | — | $1.59 B | — | -9.92% | -36.21% | $8.4 / $3.21 | $0.68 |
| 7. | BioAtla, Inc. | $5.69 | — | $7.61 M | — | 732.7% | 543.76% | $71.5 / $3.92 | $-0.6 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -2.7 M | -2.52 M | -2.55 M | -1.95 M | -1.98 M | — |
| Net Profit | -2.66 M | -2.29 M | -2.36 M | -1.86 M | -1.84 M | — |
| EPS in Rs | -0.31 | -0.27 | -0.28 | -0.22 | -0.22 | -0.2 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -9.72 M | -5.93 M | -1.8 M | -1.33 M |
| Net Profit | -9.16 M | -5.86 M | -2.04 M | -1.4 M |
| EPS in Rs | -1.08 | -0.69 | -0.24 | -0.16 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 5.97 M | 13.03 M | 3.56 M | 2.69 M |
| Total Liabilities | 2.57 M | 2.61 M | 3.94 M | 1.31 M |
| Equity | 3.4 M | 10.42 M | -0.38 M | 1.37 M |
| Current Assets | 3.94 M | 10.82 M | 1.21 M | 1.47 M |
| Current Liabilities | 1.57 M | 1.33 M | 2.42 M | 0.63 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -6.5 M | -8.51 M | -1.18 M | -1.26 M |
| Investing CF | -0.15 M | -0.36 M | -0.31 M | -0.09 M |
| Financing CF | -0.03 M | 18.52 M | 1 M | 1.36 M |
| Free CF | -6.67 M | -8.9 M | -1.47 M | -1.44 M |
| Capex | -0.17 M | -0.4 M | -0.29 M | -0.19 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -187.55% | -46% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.